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Abstract
Background: To evaluate the efficacy of highly-active antiretroviral therapy (HAART) in individuals taking
cytochrome P450 enzyme-inducing antiepileptics (EI-EADs), we evaluated the virologic response to HAART with or
without concurrent antiepileptic use.
Methods: Participants in the US Military HIV Natural History Study were included if taking HAART for ≥6 months
with concurrent use of EI-AEDs phenytoin, carbamazepine, or phenobarbital for ≥28 days. Virologic outcomes were
compared to HAART-treated participants taking AEDs that are not CYP450 enzyme-inducing (NEI-AED group) as
well as to a matched group of individuals not taking AEDs (non-AED group). For participants with multiple HAART
regimens with AED overlap, the first 3 overlaps were studied.
Results: EI-AED participants (n = 19) had greater virologic failure (62.5%) compared to NEI-AED participants (n =
85; 26.7%) for the first HAART/AED overlap period (OR 4.58 [1.47-14.25]; P = 0.009). Analysis of multiple overlap
periods yielded consistent results (OR 4.29 [1.51-12.21]; P = 0.006). Virologic failure was also greater in the EI-AED
versus NEI-AED group with multiple HAART/AED overlaps when adjusted for both year of and viral load at HAART
initiation (OR 4.19 [1.54-11.44]; P = 0.005). Compared to the non-AED group (n = 190), EI-AED participants had
greater virologic failure (62.5% vs. 42.5%; P = 0.134), however this result was only significant when adjusted for viral
load at HAART initiation (OR 4.30 [1.02-18.07]; P = 0.046).
Conclusions: Consistent with data from pharmacokinetic studies demonstrating that EI-AED use may result in
subtherapeutic levels of HAART, EI-AED use is associated with greater risk of virologic failure compared to NEI-AEDs
when co-administered with HAART. Concurrent use of EI-AEDs and HAART should be avoided when possible.
Background
Seizure disorders are common in HIV-infected indivi-
duals, with an incidence of up to 11% in several cohort
studies[1-3]. Antiepileptic drugs (AEDs) are frequently
prescribed to patients with HIV not only for pre-existing
epilepsy, but also in the setting of CNS opportunistic
infections and for other neurologic and psychiatric con-
ditions including neuropathy, refractory headaches,
depression, and bipolar disorder[4]. Concurrent use of
highly-active antiretroviral therapy (HAART) and AEDs
has the potential for highly complex and clinically sig-
nificant drug interactions.
Several first-generation AEDs, including phenytoin,
carbamazepine, and phenobarbital are metabolized by
the cytochrome P450 (CYP450) enzyme system. This
pathway of drug metabolism is also utilized by protease
inhibitors (PIs), non-nucleoside reverse transcriptase
inhibitors (NNRTIs), and the CCR5 inhibitor maraviroc
[4,5]. In addition to competing for enzyme binding sites,
some antiretrovirals and AEDs intrinsically induce
CYP450 metabolism with the potential to decrease
blood levels of both agents. As a consequence, this drug
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predispose patients to adverse HIV treatment outcomes,
including virologic failure, accumulation of antiretroviral
drug resistance mutations, and HIV disease progression.
In turn, lower AED blood levels may also have deleter-
ious effects due to lack of efficacy, including loss of sei-
zure control or inadequate control of neuropathic pain.
In many parts of the world where HIV is highly preva-
lent, such as sub-Saharan Africa and parts of Asia, only
CYP450 enzyme-inducing AEDs (EI-AEDs) are available
[6]. Thus, treating both HIV and epilepsy in these areas
may lead to suboptimal treatment of both conditions due
to the potential for clinically significant drug interactions.
The US Department of Health and Human Services
(DHHS) guidelines[7] recommend considering alterna-
tive anticonvulsants or monitoring drug levels, while
WHO guidelines[8] recommend cautious use, drug level
monitoring, or avoidance of these combinations. Since
there are inadequate clinical data and the virologic effi-
cacy is largely unknown for HAART in the setting of
concurrent EI-AED use, we performed a retrospective
case control study to determine the virologic outcomes
in participants with concomitant HAART/EI-AED use in
the US military HIV Natural History Study (NHS).
Methods
Participants were identified in the database of over 5,000
patients enrolled in the NHS since 1986, a cohort of con-
senting military members, retirees, and beneficiaries 18
years or older with HIV[9,10]. Individuals are seen
approximately every 6 months at participating United
States military treatment facilities. Data are systematically
collected, including demographic characteristics, infor-
mation on medication use, laboratory data, and reports
of clinical events with medical record confirmation.
The NHS database was searched for individuals on
concurrent HAART and EI-AEDs, which included phe-
nytoin, carbamazepine, and phenobarbital. HAART regi-
mens were PI- or NNRTI-based as previously defined
[10]. Regimens consisting only of triple nucleoside
reverse transcriptase inhibitors (NRTIs) were excluded
due to the lack of drug interactions between EI-AEDs
and the NRTI class. Participants included were those tak-
ing a PI- or NNRTI-based HAART regimen for ≥6c o n -
secutive months and during this period were taking an
EI-AED drug for ≥28 consecutive days. Since participants
in the EI-AED group may have taken medications that
can affect CYP450 metabolism other than HAART and
EI-AEDs, use of rifamycin antibiotics (CYP450 inducers)
and azole antifungals (CYP450 inhibitors) were reported.
Comparison Groups
Two control groups were used for comparisons to the
EI-AED group, the first consisted of participants
prescribed AEDs that are not CYP450 enzyme-inducing,
the NEI-AED group. NEI-AEDs included levetiracetam,
lamotrigine, zonisamide, ethosuxamide, topiramate,
gabapentin, tiagabine, and pregabalin. Oxcarbamazepine
(a weak CYP450 inducer) and valproic acid (a CYP450
inhibitor) were excluded. Since participants in the EI-
AED group were prescribed AEDs primarily for seizure
treatment and prophylaxis as well as neuropathy, partici-
pants in the NEI-AED group were restricted to those
taking these drugs for the same indications. Analogous
to the EI-AED group, the NEI-AED group was required
to have a HAART duration ≥ 6m o n t h sa n da nA E D
overlap during the HAART period of ≥28 days.
The second control group was a subgroup of all partici-
pants on HAART without any AED use in the NHS
(non-AED group), matched (10:1) to each EI-AED
patient according to year of HAART initiation and num-
ber of previous HAART regimens. Participants in this
control group must have been on their HAART regimen
for ≥ 6m o n t h st ob ei n c l u d e d .S i n c ea l lc a s e si nt h eE I -
AED group had a documented date of HIV infection
prior to the year 2000, all potential controls were limited
to those with dates of HIV infection prior to 2000.
Virologic Outcomes
Virologic failure was defined as having all plasma viral
loads (VLs) in the first 6 months of HAART (minimum
of 2 values) ≥400 copies/mL and/or the participant hav-
ing 2 consecutive VLs ≥400 copies/mL after 6 months
of HAART. Other virologic outcomes assessed included
the percentage of participants with VL <400 copies/mL
at 6 and 12 months of HAART, and the average of VL
(log10) for each individual within the HAART period.
For virologic suppression at 6 and 12 months, the VL
closest to 6 and 12 months after HAART initiation,
respectively, were used.
Statistical Methods
Logistic regression was used to compare the proportion
with virologic failure and viral suppression after starting
HAART in the EI-AED and each of the comparison
groups. For each outcome, the number and percent of
participants with the outcome are reported with the
relative odds and 95% CI, cases versus controls. Analysis
of variance and covariance was used to compare cases
and controls for average VLs during HAART. Mean
case-control differences are reported ± standard error
(SE). Because some individuals in the EI-AED and NEI-
AED groups had multiple HAART episodes with con-
c u r r e n tA E Du s e ,G E Ea n a l y s e sw a su s e dt oc o m p a r e
virologic outcomes using multiple HAART/AED overlap
episodes (up to the first 3 episodes). For binary out-
comes, a logic link was used in the GEE analyses; for
continuous outcomes a normal link was used.
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formed. For the analyses comparing the EI-AED and
NEI-AED groups, a model adjusting for year of and VL
prior to HAART initiation was performed. For compari-
son of the EI-AED and non-AED groups, adjustment
w a sm a d eo n l yf o rp r i o rV L ,s i n c ec a s e sw e r em a t c h e d
to controls for year starting HAART. SAS, version 9.2
was used for all analyses; PROC GENMOD was used for
the GEE analyses.
Results
Baseline and Demographic Factors
Based on inclusion criteria, 19 participants were treated
concurrently with EI-AEDs and HAART, with 12, 6, and
1 taking phenytoin, carbamazepine, and phenobarbital
for the first HAART/EI-AED overlap period, respec-
tively. EI-AEDs were used for seizure disorder in 17 of
19 participants; further characterization of seizure disor-
ders included CNS toxoplasmosis (2 with seizures, 1 for
prophylaxis), herpes simplex meningitis/encephalitis (n
= 2), progressive multifocal leukoencephalopathy (n =
1), seizures following a motor vehicle accident (n = 1),
and the remainder with seizure disorders without
further characterization (n = 10). Two individuals used
EI-AEDs for neuropathic pain. For the NEI-AED group,
85 participants met inclusion criteria; 82 received gaba-
pentin, 2 pregabalin, and 1 levetiracetam at the first
overlap. The majority of participants were prescribed
NEI-AEDs for the indication of neuropathic pain (81/85,
95%), with the remainder for seizure disorder (4/85,
5%). Two participants were prescribed rifampin and 1
participant had a history of itraconazole use, however
none of these medications were prescribed during the
HAART periods investigated in this study.
Demographic factors including age at HIV diagnosis
and race were similar between the EI-AED, NEI-AED
and non-AED groups. However, participants in the EI-
AED group were younger at first HAART/AED overlap
compared to the NEI-AED group (40.1 vs. 45.1 years, P
= 0.027; Table 1), reflective of the EI-AED group start-
ing HAART during an earlier calendar year (median
1998 versus 2003). Mean CD4 cell count and log10 VL
at HAART initiation were similar between the 3 groups,
although VL levels tended to be higher in the EI-AED
compared to the NEI-AED group (3.8 versus 3.1 log10
copies/mL; P = 0.075). The EI-AED group had a higher
proportion of individuals with AIDS-defining events
prior to the HAART period analyzed, however this was
only significant in comparison to the non-AED group
(57.9% vs. 21.1%; P < 0.001). The majority of partici-
pants in all groups were HAART treatment experienced,
however the EI-AED group had a higher percentage of
HAART-naive individuals (21.1%) compared to the NEI-
AED group (7.1%; P = 0.01).
In evaluating HAART/AED overlap periods, 7 (36.8%)
EI-AED participants had a single period of overlap,
while 5 (26.3%) and 7 individuals (36.8%) had 2 or ≥3
overlap periods, respectively. The number of overlaps
was similar for the NEI-AED group. The duration of
first HAART/AED overlap was no different between the
groups, with 7.0 months (range 1.0-96.4) overlap in the
EI-AED group compared to 9.1 months (1.3-65.4) for
the NEI-AED group (P = 0.231). The groups were also
similar when all eligible HAART/AED periods were
considered, with 21.3 (1.0-155.4) and 22.1 (1.6-120.3)
months of overlap for the EI-AED and NEI-AED
groups, respectively (P = 0.798).
EI-AED Group versus NEI-AED Group
In comparing outcomes for the first HAART/AED over-
lap, virologic failure was significantly greater in the EI-
AED group (62.5%) compared to the NEI-AED group
(26.7%; P = 0.009; Table 2). The average log10 VL during
the overlap period was also higher in the EI-AED group
(3.3 ± 1.3 vs. 2.4 ± 1.2; P = 0.006). The percentage of
participants with VL <400 copies/mL was significantly
lower in the EI-AED group compared to the NEI-AED
group at 6 months (33.3% vs. 71.4%; P = 0.016) and 12
months (36.4% vs. 75%; P = 0.018), respectively.
Results were similar when multiple HAART/AED over-
lap periods per individual were included in the analyses,
which added approximately twice the number of HAART/
AED episodes (Table 2). Virologic failure was more com-
mon in HAART episodes for EI-AED (63.3%) compared to
NEI-AED individuals (27.9%; P = 0.006) and the average
log10 VL during the overlap period was significantly higher
i nt h eE I - A E Dg r o u p( 3 . 3±1 . 3v s .2 . 5±1 . 3 ;P=0 . 0 0 5 ) .
The percentage of participant HAART episodes with VL <
400 copies/mL was also lower in the EI-AED group com-
pared to the NEI-AED group at 6 months (28.6% vs. 69.4%;
P = 0.002) and 12 months (39.1% vs. 74%; P = 0.004).
EI-AED Group versus NEI-AED Group - Multivariate
Analyses
Analysis of virologic outcomes adjusting for year of and
VL at HAART initiation yielded similar odds ratios to that
in the univariate analyses. This was true for both analyses
of the initial overlap period and in using multiple overlaps.
However, only for the multiple overlap analyses were the
odds ratios significantly different from one. The estimated
odds ratio for virologic failure for the EI-AED group com-
pared to the NEI-AED group using multiple episodes was
4.19 (95% CI [1.54-11.44]; P = 0.005).
EI-AED Group versus non-AED Group - Univariate and
Multivariate Analyses
For the EI-AED group, virologic failure was higher com-
pared to the non-AED group (62.5% vs. 42.5%) in
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Characteristic EI-AED NEI-AED Non-AED EI-AED
vs.
NEI-AED
(p-
values)
EI-AED
vs.
Non-AED
(p-
values)
Number, n 19 85 190
Demographics (n, % or mean ± SD)
Age at HIV diagnosis (y) 30.2 ± 10.0 32.5 ± 8.9 30.0 ± 7.9 0.331 0.912
Age at first HAART/AED overlap or index HAART (y) 40.1 ± 8.7 45.1 ± 9.0 38.7 ± 9.1 0.027 0.522
Female 1 (5.3) 13 (15.3) 18 (9.5) 0.249 0.544
Race/ethnicity 0.323 0.137
European American 13 (68.4) 46 (54.1) 89 (46.8)
African American 6 (31.6) 32 (37.6) 84 (44.2)
Other 0 (0.0) 7 (8.2) 17 (8.9)
Year of HIV diagnosis (median, range) 1988 (1985 -
2000)
1990 (1986 -
1999)
1990 (1985 -
2000)
0.145 0.122
CD4+ at HIV diagnosis (cells/uL) 632 ± 398 525 ± 321 483 ± 235 0.340 0.068
CD4+ at first HAART/AED overlap or index HAART (cells/uL) 310 ± 290 380 ± 247 364 ± 232 0.329 0.392
Viral load (log10) at first HAART/AED overlap or index HAART
(copies/mL)
3.8 ± 1.6 3.1 ± 1.4 3.6 ± 1.4 0.075 0.572
AIDS-defining event prior to first HAART/AED overlap or index
HAART
11 (57.9) 35 (41.2) 40 (21.1) 0.187 <.001
HAART regimen at first HAART/AED overlap or index HAART (n,
%)
0.189 0.543
PI-based 12 (63.2) 35 (41.2) 117 (61.6)
NNRTI-based 5 (26.3) 29 (34.1) 36 (18.9)
PI + NNRTI 2 (10.5) 21 (24.7) 37 (19.5)
Number of HAART/AED overlap periods (n, %) 0.343 —
1 7 (36.8) 47 (55.3) —
2 5 (26.3) 17 (20.0) —
≥ 3 7 (36.8) 21 (24.7) —
Months of HAART/AED overlap (median, range)
First overlap period 7.0 (1.0 - 96.4) 9.1 (1.3 - 65.4) — 0.231 —
All overlap periods 21.3 (1.0 - 155.4) 22.1 (1.6 - 120.3) — 0.798 —
Year of first HAART/AED overlap or index HAART (median,
range)
1998 (1996 -
2006)
2003 (1996 -
2009)
1998 (1996 -
2006)
0.002 1.000
HAART use prior to first HAART/AED overlap or index HAART (n,
%)
0.010 0.523
No prior HAART 4 (21.1) 6 (7.1) 40 (21.1)
<1 year 4 (21.1) 7 (8.2) 37 (19.5)
1-2 years 2 (10.5) 7 (8.2) 31 (16.3)
2-3 years 4 (21.1) 6 (7.1) 17 (8.9)
>3 years 5 (26.3) 59 (69.4) 65 (34.2)
Duration of first HAART/AED overlap or index HAART (n, %) 0.144 0.495
<1 year 10 (52.6) 22 (25.9) 69 (36.3)
1-2 years 4 (21.1) 22 (25.9) 63 (33.2)
2-3 years 2 (10.5) 15 (17.6) 31 (16.3)
>3 years 3 (15.8) 26 (30.6) 27 (14.2)
EI-AED, enzyme-inducing antiepileptics (phenytoin, carbamazepine, phenobarbital); NEI-AED, antiepileptics that are not enzyme-inducing; Non-AED, subgroup of
all subjects in the cohort (exclusive of other groups) matched according to year of HAART start and number of previous HAART regimens; PI, protease inhibitor;
NNRTI, non-nucleoside reverse transcriptase inhibitor
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cal significance (P = 0.134; Table 3). Similar results were
observed for other virologic outcomes, with less virolo-
gic suppression to <400 copies/mL at 6 months (OR
0.40 [0.12-1.38]; P = 0.146) and 12 months (OR 0.32
[0.09-1.16]; P = 0.083) for the EI-AED group compared
to the non-AED group, respectively. Correspondingly,
average log10 VL during the overlap period was higher
in the EI-AED group than in the non-AED group (3.3 ±
1.3 vs. 2.9 ± 1.2; P = 0.198). When adjusted for VL at
HAART initiation, there was significantly greater virolo-
gic failure in the EI-AED group compared to the non-
AED group (OR 4.30 [1.02-18.07]; P = 0.046). The
adjusted odds of virologic suppression was lower in the
EI-AED than in the non-AED group at 6 and 12
months, with the latter being statistically significant (OR
0.17 [0.03-0.89]; P = 0.036).
Discussion
HIV-infected patients commonly require treatment with
AEDs due to neurologic and psychiatric conditions.
Drug interactions between EI-AEDs and HAART are
highly complex and may result in loss of efficacy for
one or both treatments. In examining this interaction
retrospectively in a military HIV cohort with free access
to healthcare and medications, we found greater virolo-
gic failure in individuals taking EI-AEDs compared to
NEI-AEDs when used in combination with HAART.
Since first line agents for epilepsy in most low and mid-
dle income countries are limited to EI-AEDs, the clinical
Table 2 Virologic Outcomes of EI-AED Compared to NEI-AED Subjects
EI-AED
(N = 19)
NEI-AED
(N = 85)
OR (95% CI) or
Difference ± SE
Adjusted for Year of and VL at
HAART Initiation
OR (95% CI) or
Difference ± SE
First HAART/AED Overlap
Virologic failure 10/16 (62.5%) 20/75 (26.7%) 4.58 (1.47 - 14.25)
P = 0.009
4.67 (0.92 - 23.62)
P = 0.062
Average VL during period (log10) 3.3 ± 1.3 (n = 19) 2.4 ± 1.2 (n = 84) 0.8 ± 0.3;
P = 0.006
0.2 ± 0.3;
P = 0.376
VL <400 at 6 months 4/12 (33.3%) 50/70 (71.4%) 0.20 (0.05 - 0.74)
P = 0.016
0.35 (0.06 - 2.07)
P = 0.247
VL <400 at 12 months 4/11 (36.4%) 42/56 (75.0%) 0.19 (0.05 - 0.75)
P = 0.018
0.17 (0.02 - 1.42)
p = 0.102
All HAART/AED Overlaps*
Virologic failure 19/30 (63.3%) 34/122 (27.9%) 4.29 (1.51 - 12.21)
P = 0.006
4.19 (1.54 - 11.44)
P = 0.005
Average VL during period (log10) 3.3 ± 1.3 (n = 34) 2.5 ± 1.3 (n = 142) 0.9 ± 0.3
P = 0.005
0.7 ± 0.3
P = 0.007
VL <400 at 6 months 8/28 (28.6%) 84/121 (69.4%) 0.17 (0.06 - 0.53)
P = 0.002
0.25 (0.07 - 0.86)
P = 0.028
VL <400 at 12 months 9/23 (39.1%) 71/96 (74.0%) 0.21 (0.07 - 0.61)
P = 0.004
0.22 (0.06 - 0.75)
P = 0.016
OR (odds ratio): Odds of virologic event for EI-AED cases versus odds for NEI-AED controls; VL, viral load (copies/mL); * Up to three intervals used per subject
Table 3 Virologic Outcomes of EI-AED Compared to Non-AED Subjects
EI-AED
(N = 19)
Non-AED
(N = 190)
OR (95% CI) or
Difference ± SE
Adjusted for VL at
HAART Initiation
OR (95% CI) or
Difference ± SE
First HAART/AED Overlap
Virologic failure 10/16 (62.5%) 62/146 (42.5%) 2.26 (0.78 - 6.54)
P = 0.134
4.30 (1.02 - 18.07)
P = 0.046
Average VL during period (log10) 3.3 ± 1.3 (n = 19) 2.9 ± 1.2 (n = 184) 0.4 ± 0.3;
P = 0.198
0.3 ± 0.3;
P = 0.195
VL <400 at 6 months 4/12 (33.3%) 89/160 (55.6%) 0.40 (0.12 - 1.38)
P = 0.146
0.30 (0.06 - 1.48)
P = 0.139
VL <400 at 12 months 4/11 (36.4%) 80/125 (64.0%) 0.32 (0.09 - 1.16)
P = 0.083
0.17 (0.03 - 0.89)
P = 0.036
OR (odds ratio): Odds of virologic event for EI-AED cases versus odds for non-AED controls; VL, viral load (copies/mL)
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be substantial.
Despite the widespread use of EI-AEDs and the poten-
tial for significant drug interactions with HAART, clini-
cal studies are extremely limited[11]. A randomized,
parallel-arm study examined the pharmacokinetic inter-
action between lopinavir/r i t o n a v i r( 4 0 0m g / 1 0 0m g
twice daily) and phenytoin (300 mg daily) in healthy
volunteers[12]. In the first arm of 12 participants, the
addition of phenytoin reduced the area under the con-
centration-time curve (AUC) of lopinavir and ritonavir
by 33% and 28%, respectively after 12 days of overlap
compared to the pre-phenytoin period. Notably, the
effect of increased lopinavir clearance secondary to
CPY3A4 induction by phenytoin was not offset by the
presence of low dose ritonavir used as a “boosting”
agent. The second arm of 8 participants showed a 31%
reduction in phenytoin AUC after the addition of lopi-
navir/ritonavir demonstrating a two-way drug interac-
tion between classes. A similar result was shown in a
randomized, crossover study of 18 healthy individuals
receiving either efavirenz (600 mg daily) or carbamaze-
pine (titrated to 400 mg daily) followed by 14-21 days of
overlap with the other drug[13]. Compared to pre-over-
lap levels, efavirenz AUC and minimum (Cmin) and
maximum (Cmax) concentrations were reduced by
approximately 17% to 43% while carbamazepine AUC
decreased by 27%. Though the majority of drug-drug
interactions result in reduced plasma concentrations,
carbamazepine toxicity may occur secondary to inhibi-
tion of CYP3A4 when used with low dose ritonavir
[4,14]. Since most studies were performed in healthy
volunteers, extrapolation of these findings to patients
with HIV infection and epilepsy is difficult because the
clinical implications of these interactions have not been
adequately studied.
This is the first study demonstrating clinically mean-
ingful outcomes in participants receiving overlapping
treatment with EI-AEDs and HAART. The impact is so
r o b u s t ,t h a tw ew e r ea b l et od e m o n s t r a t et h i sd e s p i t e
the small number of individuals receiving EI-AEDs.
S i n c ei ti sm o r ed i f f i c u l tt oenter military service with
pre-existing epilepsy, the overall incidence of epilepsy is
low in our cohort. Yet, the close follow-up in this pro-
spective observational cohort makes it uniquely ideal for
an assessment of clinical consequences of this interac-
tion. Despite the small number of participants taking
EI-AEDs in our study, these agents are still commonly
used even in the United States. EI-AEDs are favored by
some insurance plans due to their lower cost, so it is
likely that a cohort with a higher prevalence of epilepsy
would have included more participants on EI-AEDs. It
is notable that of the 21 participants diagnosed with a
seizure disorder in this study, 17 were taking EI-AEDs.
The comparison of EI-AEDs versus NEI-AEDs com-
bined with HAART in our study showed worse virologic
outcomes in the EI-AED group. The inclusion criteria
for the NEI-AED group were chosen to best approxi-
mate the participants in the EI-AED group, specifically
targeting use of NEI-AEDs for the indications of seizure
disorder or neuropathic pain. In cases where the specific
indication for AED use was known, the majority of indi-
viduals were prescribed AEDs in the setting of CNS
opportunistic infections. The relatively small number of
individuals in the EI-AED group limited the power of
the study. This was likely due to the increased availabil-
ity of newer AEDs that are not CYP450-enzyme indu-
cing over the past decade. Other limitations include the
differing proportions of seizure disorders and neuro-
pathic pain in the two groups. As a reflection of this,
the drugs in the NEI-AED group are agents commonly
used for neuropathic pain. Multivariate analyses were
performed in an attempt to minimize some of the differ-
ences in HAART period between groups, with results
demonstrating worse virologic outcomes in the EI-AED
group. Other unmeasured factors included HIV drug
resistance, potency of HAART regimens, adherence to
both drug classes, absence of ARV and AED blood
levels, and the inability to study individual EI-AED and
ARV pairings due to small sample size. The EI-AED
group also had a higher percentage of AIDS events and
higher VL prior to the first AED/HAART overlap com-
pared to NEI-AED group. This suggests that the EI-
AED group may have more advanced HIV disease and
greater risk of virologic failure. It is important to note,
however, that the EI-AED group had less treatment
experience than the NEI-AED group, with 42% and 15%
having <1 year of HAART experience, respectively. This
difference in treatment experience in the EI-AED group
may potentially offset the risk of treatment failure posed
by having a higher percentage of prior AIDS events.
For comparison with both NEI-AED and non-AED
control groups, the EI-AED group had consistently
worse virologic outcomes, especially in multivariate ana-
lyses. Non-AED individuals fared better than EI-AED
participants, however the results were significant only
after adjustment for VL at HAART initiation. There are
several unmeasured factors that may have contributed
to these findings including medication doses and adher-
ence, HIV drug resistance, and other uncharacterized
variables unique to patients with seizure disorders or
neuropathic pain. Measures of AED efficacy, including
seizure control, were not completely captured. Our
initial hypothesis was that concurrent HAART/EI-AED
use would lead to subtherapeutic blood levels of
HAART, elevated VLs, and eventually virologic failure.
We chose a minimum HAART/AED overlap period of
≥28 days due to the small number of patients exposed
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all overlaps was 9 months for the EI-AED group. Since
epilepsy and seizure disorders typically require long-
term, if not life-long treatment, many patients will be
taking EI-AEDs and HAART for extended periods of
time. Even though the percentage of participants with
virologic failure was high at 63.3%, it is possible that the
HAART/EI-AED overlap time was insufficient to
develop regimen failure for some individuals and addi-
tional failures would occur with continued use of both
classes.
The introduction of EI-AEDs in patients with HIV
may complicate a regimen that is already subject to
other challenges from drug interactions. For example,
the burden of tuberculosis in sub-Saharan Africa
requires many HIV-infected patients to receive concur-
rent antituberculous treatment (ATT). The cornerstone
of ATT regimens is the rifamycin class of antibiotics. As
inducers of CYP450, rifamycins can also enhance the
metabolism of AEDs and antiretrovirals, adding further
management challenges[15]. Compared to rifampin, rifa-
butin has less CYP450 induction and is favored for ATT
in the setting of HAART. In the current study, no parti-
cipants were treated for active tuberculosis during the
study period.
The World Health Organization’s list of essential
medicines includes the EI-AEDs carbamazepine, pheny-
toin, and phenobarbital[16]. In addition to the availabil-
i t yo fo n l yE I - A E D si nm a n ya r e a so ft h ew o r l d ,t h e
expanding use of AEDs in patients with HIV has made
the management of HIV and comorbid conditions chal-
lenging in these locations, as well as in more developed
countries. For example, distal sensory polyneuropathy
(DSP), often treated with AEDs, occurs in up to 57% of
patients with HIV and the risk of developing DSP is
increased with underlying nutritional deficiencies[17-19].
In the setting of concurrent HAART/EI-AED use, the
US Department of Health and Human Services (DHHS)
guidelines[7] recommend providers consider use of
alternative agents and/or monitoring of blood levels of
HAART/EI-AEDs. Therapeutic drug monitoring (TDM)
of HAART is not routinely recommended for the man-
agement of HIV patients. However, DHHS guidelines
suggest that TDM may be useful in situations with clini-
cally significant drug-drug interactions that may result
in reduced efficacy, including use of certain AEDs.
TDM may identify reduced blood levels of HAART as a
result of drug-drug interactions prompting the provider
to consider increasing the dose of ARVs. However, this
may lead to a higher rate of adverse effects and ulti-
mately impact drug tolerance and adherence.
Despite the potential merits of this approach, TDM
has several limitations including cost and limited avail-
ability. According to a recent Cochrane review[20],
TDM trials are generally small and underpowered, have
short follow-up time, and poor compliance with TDM
recommendations. TDM trials have also been performed
in countries with higher income and may not be gener-
alized to resource-limited settings. Since the majority of
EI-AED use is in low and middle income countries due
to the greater cost of NEI-AEDs, TDM is unlikely to be
an option for clinicians in these areas.
In settings where EI-AEDs must be used, it is impor-
tant to recognize treatment failure early with frequent
VL monitoring and clinical assessments for efficacy of
HAART and EI-AEDs. HAART regimens composed of
the integrase inhibitor raltegravir in combination with 2
NRTIs would enable clinicians to avoid drug-drug inter-
actions, however raltegravir may not be available in
many areas. Although there are concerns that a triple
NRTI regimen may be less durable compared to other
HAART regimens, this may be another reasonable
option given the lack of drug interactions between
NRTIs and EI-AEDs[21].
For the treatment of epilepsy in the setting of HIV infec-
tion, alternative agents to EI-AEDs should be administered
if available. Valproic acid is available in many regions,
however this drug is a weak inhibitor of CYP450 and may
lead to increased HAART levels and toxicity, especially
when used with lopinavir/ritonavir[4,22]. Due to its addi-
tional property as a non-selective histone deacyltase
(HDAC) inhibitor, in vitro studies indicate valproic acid
may increase HIV outgrowth from resting CD4+ T cells
[ 2 3 ] .H o w e v e r ,t h ein vivo effects and clinical relevance
have not been firmly established[24,25]. Despite the poten-
tial concerns, valproic acid appears to be a safe alternative
to EI-AEDs when used with HAART[26].
Conclusions
EI-AEDs should be avoided in favor of NEI-AEDs in
patients requiring concurrent HAART and AED therapy
due to the higher potential of virologic failure and
reduced efficacy. In areas where EI-AED use cannot be
avoided, closer and more frequent monitoring of HIV
and seizure control is warranted. Alternative HAART
regimens, such as triple NRTIs or integrase-based regi-
mens, and use of TDM may be beneficial in managing
or avoiding these complex drug interactions when avail-
able. In low to middle income regions such as sub-
Saharan Africa and parts of Asia, treatment of HIV and
comorbid epilepsy and other neurologic conditions will
continue to pose great challenges until additional
resources become available, such as NEI-AEDs and a
wider repertoire of antiretrovirals.
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